Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Tryton initiates enrollment in Side Branch Stent System study

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first U.S. patient has been enrolled in the pivotal trial to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery disease.

27 Jan 2011

Boston Scientific initiates enrollment in comparative Chinese study of PROMUS Element Everolimus-Eluting Stent

Boston Scientific Corporation today announced the beginning of patient enrollment in the PLATINUM China clinical trial, which is designed to evaluate the safety and effectiveness of the Company's PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent compared to the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent in the treatment of patients with a single de novo atherosclerotic lesion.

27 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

NYSE Amex accepts Cardium's exchange listing compliance plan

Cardium Therapeutics reported that its exchange listing compliance plan submitted on December 2, 2010 has been accepted by the NYSE Amex LLC.

24 Jan 2011

Grayscale IVUS and VH IVUS tissue characterization software help accurate assessment of blockage risk

Volcano Corporation today announced the publication of results from the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study in The New England Journal of Medicine showing that grayscale intravascular ultrasound (IVUS) and Volcano's proprietary VH® IVUS tissue characterization software enable physicians to more accurately assess the risk of individual blockages than the use of the current standard-of-care-- angiographic imaging-- alone.

20 Jan 2011

Message of health benefits of moderate drinking are hazardous and extremely dangerous

A Letter to the Editor entitled "What should we advise about alcohol consumption?" was recently published by Maurizio Ponz de Leon in Intern Emerg Med.1 Dr. de Leon argues that the message of health benefits of moderate drinking "seems to me hazardous and extremely dangerous to diffuse in the general population."

20 Jan 2011

Revolution R Enterprise implemented at CardioDX

Revolution Analytics, the leading provider of commercial software and support for the popular open source R statistics language, today announced the successful implementation of its signature product, Revolution R Enterprise, by biostatisticians at CardioDX, a genomic research firm.

19 Jan 2011

Uric acid levels linked to severe osteoarthritis

The amount of uric acid in one's joints may increase the likelihood of severe osteoarthritis, the most common form of arthritis worldwide, according to researchers at Duke University Medical Center.

19 Jan 2011

Cholesterol efflux capacity is more closely associated with protection against heart disease: Study

The discovery that high levels of high-density lipoprotein cholesterol is associated with reduced risk of cardiovascular disease has fostered intensive research to modify HDL levels for therapeutic gain. However, recent findings have called into question the notion that pharmacologic increases in HDL cholesterol levels are necessarily beneficial to patients.

13 Jan 2011

5 easy steps to improve heart health

Did you know that a good night's sleep can help prevent heart disease? There are many simple ways to lower your risk.

12 Jan 2011

Stereotaxis announces first successful cardiac ablation procedure with Vdrive robotic navigation system

Stereotaxis, Inc. announces the first successful cardiac ablation procedure with the Vdrive™ robotic navigation system as the company received CE Mark for this latest innovation.

11 Jan 2011

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.

10 Jan 2011

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

NovaDel Pharma Inc. today announced that it has received a $500,000 milestone payment from Akrimax Pharmaceuticals. The milestone payment was received in connection with the license and distribution agreement, dated October 27, 2009, between NovaDel Pharma Inc. and Mist Acquisition, LLC, an affiliate of Akrimax Pharmaceuticals.

7 Jan 2011

Stereotaxis extends strategic partnership to distribute magnetic ablation catheters

Stereotaxis, Inc. announced today that the Company and its existing strategic catheter partner have extended their exclusive worldwide agreement for the distribution of existing approved magnetic ablation catheters through the end of 2015.

6 Jan 2011

Deceptive food labels lead to increased risk of deadly diseases

Did you know that when you pick up a product promoted as trans fat free, you may still be ingesting a significant amount of this potentially harmful substance? An article by Case Western Reserve University School of Medicine student Eric Brandt, published in the January/February 2011 issue of the American Journal of Health Promotion, reveals that misleading labeling practices can result in medically significant intake of harmful trans fat, despite what you read on Food and Drug Administration (FDA) approved labels.

3 Jan 2011

InfraReDx to receive $862,000 as part of MLSC Tax Incentive Program

InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has been selected to receive an award of nearly $862,000 as part of the Massachusetts Life Sciences Center Tax Incentive Program. In conjunction with the award, InfraReDx has committed to create 32 new jobs during 2011.

24 Dec 2010

FDA approves Novartis' Amturnide for treatment of high blood pressure

Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure. Amturnide combines the only approved direct renin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).

23 Dec 2010

Top ten advances in cardiovascular, stroke research in 2010

Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research recognized by the American Heart Association/American Stroke Association.

22 Dec 2010

Tryton initiates enrollment in Side Branch Stent System trial for coronary artery disease

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first patient has been enrolled in the pivotal trial to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery disease.

20 Dec 2010

Stereotaxis closes $40 million credit facility

Stereotaxis, Inc. announced today that the Company has closed on its previously announced $40 million credit facility, which includes a $30 million revolving facility that matures on March 31, 2012 and a $10 million term loan that matures on December 31, 2013. The new facility was led by Silicon Valley Bank, and replaces the Company's previous facility that was scheduled to mature in March 2011.

20 Dec 2010

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Tryton initiates enrollment in Side Branch Stent System study

Boston Scientific initiates enrollment in comparative Chinese study of PROMUS Element Everolimus-Eluting Stent

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

NYSE Amex accepts Cardium's exchange listing compliance plan

Grayscale IVUS and VH IVUS tissue characterization software help accurate assessment of blockage risk

Message of health benefits of moderate drinking are hazardous and extremely dangerous

Revolution R Enterprise implemented at CardioDX

Uric acid levels linked to severe osteoarthritis

Cholesterol efflux capacity is more closely associated with protection against heart disease: Study

5 easy steps to improve heart health

Stereotaxis announces first successful cardiac ablation procedure with Vdrive robotic navigation system

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

Stereotaxis extends strategic partnership to distribute magnetic ablation catheters

Deceptive food labels lead to increased risk of deadly diseases

InfraReDx to receive $862,000 as part of MLSC Tax Incentive Program

FDA approves Novartis' Amturnide for treatment of high blood pressure

Top ten advances in cardiovascular, stroke research in 2010

Tryton initiates enrollment in Side Branch Stent System trial for coronary artery disease

Stereotaxis closes $40 million credit facility

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Newsletters you may be interested in